At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 270 enrolled
Drug / intervention
Tenofovir Alafenamidedrug
Likely dose
Tenofovir Alafenamide 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)
In Brief
A Phase 4 clinical trial evaluating Tenofovir Alafenamide for Hepatitis B, Chronic. Completed, enrolled 270 participants across 12 sites in 4 countries.
Detailed Summary
Primary Objective: To describe rate of persistence and/or improvement of viral suppression with TAF as with previous anti-HBV (hepatitis B virus) treatment
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B, Chronic
CountriesJapan, South Korea, Taiwan, United States
CollaboratorsGilead Sciences
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartMay 2018
Primary CompletionApr 2022
TodayJul 2026
First PostedMar 20, 2018
Enrollment StartMay 1, 2018
Primary CompletionApr 19, 2022
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 8.3 years ago
Interventions
Tenofovir Alafenamidedrug
Tenofovir alafenamide (TAF) is a new formulation of tenofovir with higher intracellular active drug concentration allowing for dosing of only 25 mg once daily and thus can potentially lower the already low risk of renal toxicity and bone loss with tenofovir disoproxil fumarate (TDF).